about
Multigene assays and molecular markers in breast cancer: systematic review of health economic analysesA three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer.Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancerGonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials.Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitorsOvarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review.Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study.Hormonotherapy of advanced prostate cancer.First line chemotherapy of metastatic breast cancer.An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study.New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones.Adjuvant endocrine therapy for perimenopausal women with early breast cancer.New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives.Medical approaches to preservation of fertility in female cancer patients.Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.Gene expression profiling in breast cancer: a clinical perspective.Pemetrexed for the treatment of non-small cell lung cancer.The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs).Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.Treatment options in HR⁺/HER2⁻ advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?HER2-positive metastatic breast cancer: a changing scenario.Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer.Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis.Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study.Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients.Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols.Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity.Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane.5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer.
P50
Q26825362-CFE70642-73DA-4CEA-9CE1-A75A523EF602Q33337133-4DDBF363-5C59-445A-92B1-E0292BFAB800Q33369478-28F17A4D-148F-4583-B8EC-11FA7E32405BQ33495866-73369807-F565-4977-BB88-7940D4A993A2Q34393606-AC1A80BD-D345-4B5D-870E-07964ADD9253Q35460114-2846B8BF-2767-4050-8C5B-4B5F443EA405Q35583869-865C4848-9BB0-4083-B6A4-F33A6CDF9139Q35766397-2899B034-5C86-4FF4-A64A-8AEBF6790948Q35909153-5C3FC743-DAEB-412A-B711-30BBE0CAA669Q36108562-B22042F5-A0B9-4F37-B992-D841C40494EEQ36114975-D6DDA1A3-53DC-4EA9-8736-493ADACDDDE0Q36143700-11E92D38-C1D5-48F8-B733-B6D6038D92A0Q36522716-3AA138D6-37A4-4A58-BF5C-E622DA806169Q36776918-40F91CB4-99D4-4F78-AFE3-D7851255AEAFQ37057994-EF9D8177-6E61-4E76-A04D-8E015DD34920Q37335654-294B75AF-4E5F-4703-84AD-7635266A3FB6Q37373988-F7BC0644-E33E-43A5-B21A-8298919E02E4Q37781184-D9CBF7A5-BFB9-4022-9863-1E0C2538C877Q37831349-A18B98CD-109A-4AC6-B9B2-C5455744B244Q38052616-73EF356B-15EA-4308-BB0D-A9E4C4C774FDQ38086710-BCD1E140-F6CD-49B6-9B03-A83800668A01Q38107552-B48719CC-A7CC-4B1F-BD4C-82D38A4515BDQ38138232-1202018F-9B11-4774-A488-6D52882594E0Q38170384-FCED71F2-F5E3-4692-9926-C7ED34E21CBCQ38250444-1E9193D9-A51D-45AA-915A-9067DED0C1A3Q38369689-1C3A4F51-ED62-4397-8235-351B5D4A9533Q38397868-EFC51189-A0CB-402B-99B1-88265B55B4A3Q38487646-1ACBAF1B-C598-4400-8A2E-55918C6C71F1Q38613025-61C780D9-84BF-40D2-BA4E-7D64F9C009DCQ38650494-B27DAD7B-0A3E-42DB-907B-EAF4AEE8ED5AQ38690803-03279FD7-7589-4A49-920D-428F302BFBDBQ38866320-08404C11-77AA-4F3D-BEBE-CE697FB7034BQ38933237-0DB069A9-7B9D-4BDA-9EFE-8B5DB906D571Q39008777-2AFD9D88-669E-49B2-9E12-A052FB7E341DQ39388191-A1CCB668-4ACF-4BD9-8711-3143F6F771EEQ39443860-A4372346-40AE-4E07-916B-F2DF35B42264Q39670713-D698EAB0-52F9-4298-B867-FBA3312F548CQ39785684-4ED312EB-F512-4802-8FE4-3213F12DD7C2Q40127291-BF5CFB04-3797-4A4B-9FEA-DCA90B2C6BC9Q40535560-F0FAF190-E873-4870-AD95-40AF4AB58877
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
P Pronzato
@ast
P Pronzato
@en
P Pronzato
@es
P Pronzato
@nl
type
label
P Pronzato
@ast
P Pronzato
@en
P Pronzato
@es
P Pronzato
@nl
prefLabel
P Pronzato
@ast
P Pronzato
@en
P Pronzato
@es
P Pronzato
@nl
P106
P1153
7005083276
P31
P496
0000-0001-8203-2564